US NIH National Institute of Neurological Disorders and Stroke:Optimisation of non-addictive small molecules and biologics therapies to treat pain (UG3/UH3 clinical trial not allowed)

This supports preclinical optimisation and development of safe, effective, and non-addictive small molecule and biologic therapeutics to treat pain. The goal is to accelerate the optimisation and development of promising small molecule and biologic hits or leads towards clinical trials. Applicants must have a promising hit or lead, robust biological rationale for the intended approach, and identified assays for optimisation of the agent. The scope of this programme includes optimisation and early development activities, investigational new drug-enabling studies, and assembly of IND application.

This opportunity uses the UG3/UH3 Exploratory/Developmental Phased Award Cooperative Agreement mechanism.

Funding & Duration

Each project may receive up to USD $500,000 (approx. AUD $692,000) per year for a period of two years in the UG3 exploratory phase, and up to USD $1.5M (approx. AUD $2.08M) per year in the UH3 developmental phase.


Non-domestic (non-U.S.) Entities (Foreign Institutions) are eligible to apply.

Submission Requirements & Due Date

Further Information

Need Help?

This entry was posted in Engineering, Computer & Mathematical Sciences, Grants (Project Funds), Health & Medical Sciences, International Funding, Sciences and tagged . Bookmark the permalink.

Comments are closed.